Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer

Chemotherapy in nonsmall-cell lung cancer (NSCLC) is not just a reality but has resulted in important improvements in quality of life and survival for patients with locally advanced and metastatic NSCLC. For patients with stage IV NSCLC, platinum-based 2-drug combinations are superior to single-agen...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in thoracic and cardiovascular surgery 2003-10, Vol.15 (4), p.438-447
Main Authors: Ramalingam, Sakkaraiappan, Belani, Chandra P
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - secondary
Carcinoma, Non-Small-Cell Lung - therapy
chemoradiation
chemotherapy
Clinical Trials as Topic
Humans
Lung Neoplasms - secondary
Lung Neoplasms - therapy
molecularly targeted therapy
Neoplasm Recurrence, Local - therapy
Nonsmall-cell lung cancer
radiation
Radiotherapy
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy in nonsmall-cell lung cancer (NSCLC) is not just a reality but has resulted in important improvements in quality of life and survival for patients with locally advanced and metastatic NSCLC. For patients with stage IV NSCLC, platinum-based 2-drug combinations are superior to single-agent therapy and have a superior therapeutic index than 3-drug combinations. Concurrent chemoradiation has become the standard of care for patients with locally advanced NSCLC. The addition of consolidation chemotherapy following definitive chemoradiation appears to improve median survival. The era of molecularly targeted therapies for NSCLC is here. Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC.
ISSN:1043-0679
1532-9488
DOI:10.1053/S1043-0679(03)00097-2